CP-100356 is an Orally Active Dual MDR1/BCRP Inhibitor
During the drug discovery development, most new chemical entities (NCEs) suffer from limiting oral absorption after an oral administration. Besides the first-pass metabolism, some other factors such as aqueous solubility,…